Circulating tumor DNA Post-transplant lymphoproliferative disorder 18F-flurodeoxyglucose positron emission tomography/computed tomography Minimal residual disease
Conditions
Interventions
None
Sponsors
University Medical Center Groningen
Eligibility
Inclusion criteria
Inclusion criteria: - Patients having undergone a SOT or HSCT - Histologically proven CD20+ monomorphic PTLD (with or without EBV association), - Age > 18 years - Intent to treat patient according to standard protocol (rituximab / R-CHOP). Clinicians are allowed to adapt protocol in the best interest of the patient - Measurable disease on 18F-FDG-PET/CT at diagnosis according to the Lugano classification 2014 - Patient’s written informed consent and written consent for data collection.
Exclusion criteria
Exclusion criteria: - A complete surgical resection of tumor. - Upfront treatment with external beam radiation therapy. - Involvement of the central nervous system by the disease. - Known to be HIV positive. - Iatrogenic immunodeficiency lymphomas other than PTLD.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of ctDNA at diagnosis and response evaluation | — |
Secondary
| Measure | Time frame |
|---|---|
| - Sensitivity and specificity of plasma ctDNA genotyping in comparison with tumor sample DNA (gDNA) as gold standard - Changes in ctDNA abundance throughout therapy - Clinical end-points: progression free survival (PFS), overall survival (OS), event free survival (EFS), disease specific survival (DSS) | — |
Contacts
Public ContactFilipe Jesus
Outcome results
None listed